Armata Pharmaceuticals, Inc.
Clinical trials sponsored by Armata Pharmaceuticals, Inc., explained in plain language.
-
New drug combo targets tough staph blood infections
Disease control CompletedThis study tested a new medicine called AP-SA02, given alongside standard antibiotics, for adults with a serious Staphylococcus aureus bloodstream infection. The main goal was to check if the combination is safe and tolerable. Fifty-six hospitalized adults took part, and research…
Phase: PHASE1, PHASE2 • Sponsor: Armata Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
Virus-Eating therapy inhaled to fight stubborn lung bug
Disease control CompletedThis study tested an inhaled treatment called AP-PA02, which uses special viruses (phages) to attack Pseudomonas bacteria in the lungs. It involved 48 adults with bronchiectasis (a lung condition) and a long-term Pseudomonas infection. The goal was to see if the treatment is safe…
Phase: PHASE2 • Sponsor: Armata Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC